IQVIA Partners with Medera to Accelerate Cardiac Gene Therapy and Drug Discovery
Event summary
- IQVIA and Medera Inc. announced a strategic collaboration on August 4, 2026 to advance cardiac gene therapies and human-based drug discovery.
- The partnership combines IQVIA’s global clinical trial infrastructure with Medera’s Sardocor (gene therapy) and Novoheart (mini-Heart platform) platforms.
- IQVIA will support patient recruitment, data quality, and regulatory filings for Sardocor’s FDA-cleared gene therapy programs.
- Novoheart’s mini-Heart platform aims to expand into multiple organ systems under the FDA Modernization Act 2.0.
The big picture
The collaboration aligns with the growing trend of human-based drug discovery, reducing reliance on animal testing. It also underscores the increasing importance of AI-driven healthcare intelligence in accelerating clinical trials and regulatory approvals. With IQVIA’s global reach and Medera’s innovative platforms, the partnership could set a new benchmark for cardiac therapy development.
What we're watching
- Regulatory Momentum
- How the FDA’s expedited designations will impact Sardocor’s gene therapy programs.
- Platform Expansion
- The pace at which Novoheart’s mini-Heart platform scales across multiple organ systems.
- Commercialization Strategy
- Whether IQVIA’s infrastructure can accelerate Medera’s pipeline to market.